Literature DB >> 27917327

p53 Mutation: Critical Mediator of Therapy Resistance against Tumor Microenvironment.

Ali S Arbab1, Meenu Jain1, B R Achyut1.   

Abstract

Entities:  

Year:  2016        PMID： 27917327      PMCID： PMC5135095          DOI： 10.4172/2168-9652.1000e153

Source DB:  PubMed          Journal:  Biochem Physiol        ISSN： 2168-9652


× No keyword cloud information.
  45 in total

1.  Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.

Authors:  B R Achyut; Adarsh Shankar; A S M Iskander; Roxan Ara; Kartik Angara; Peng Zeng; Robert A Knight; Alfonso G Scicli; Ali S Arbab
Journal:  Cancer Lett       Date:  2015-09-21       Impact factor: 8.679

Review 2.  Can tumor angiogenesis be inhibited without resistance?

Authors:  Kathy D Miller; Christopher J Sweeney; George W Sledge
Journal:  EXS       Date:  2005

Review 3.  Using the molecular classification of glioblastoma to inform personalized treatment.

Authors:  Adriana Olar; Kenneth D Aldape
Journal:  J Pathol       Date:  2014-01       Impact factor: 7.996

Review 4.  Gain-of-function mutations in the tumor suppressor gene p53.

Authors:  M G van Oijen; P J Slootweg
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

5.  Antiangiogenic Therapy for Glioblastoma: Complex Biology and Complicated Results.

Authors:  Mark R Gilbert
Journal:  J Clin Oncol       Date:  2016-03-21       Impact factor: 44.544

6.  Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study.

Authors:  Meser M Ali; Sanath Kumar; Adarsh Shankar; Nadimpalli R S Varma; A S M Iskander; Branislava Janic; Wilson B Chwang; Rajan Jain; Abbas Babajeni-Feremi; Thaiz F Borin; Hassan Bagher-Ebadian; Stephen L Brown; James R Ewing; Ali S Arbab
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.

Authors:  Xiang Wang; Jin-Xiu Chen; Jin-Ping Liu; Chao You; Yan-Hui Liu; Qing Mao
Journal:  Ann Surg Oncol       Date:  2013-11-19       Impact factor: 5.344

9.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression.

Authors:  Stephanie M Pyonteck; Leila Akkari; Alberto J Schuhmacher; Robert L Bowman; Lisa Sevenich; Daniela F Quail; Oakley C Olson; Marsha L Quick; Jason T Huse; Virginia Teijeiro; Manu Setty; Christina S Leslie; Yoko Oei; Alicia Pedraza; Jianan Zhang; Cameron W Brennan; James C Sutton; Eric C Holland; Dylan Daniel; Johanna A Joyce
Journal:  Nat Med       Date:  2013-09-22       Impact factor: 53.440

10.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Authors:  Yu Zhu; Brett L Knolhoff; Melissa A Meyer; Timothy M Nywening; Brian L West; Jingqin Luo; Andrea Wang-Gillam; S Peter Goedegebuure; David C Linehan; David G DeNardo
Journal:  Cancer Res       Date:  2014-07-31       Impact factor: 12.701
View more
  2 in total

1.  MircoRNA-1275 promotes proliferation, invasion and migration of glioma cells via SERPINE1.

Authors:  Dong-Mei Wu; Shan Wang; Xin Wen; Xin-Rui Han; Yong-Jian Wang; Shao-Hua Fan; Zi-Feng Zhang; Qun Shan; Jun Lu; Yuan-Lin Zheng
Journal:  J Cell Mol Med       Date:  2018-07-19       Impact factor: 5.310

2.  Antimicrobial Peptide TP4 Induces ROS-Mediated Necrosis by Triggering Mitochondrial Dysfunction in Wild-Type and Mutant p53 Glioblastoma Cells.

Authors:  Bor-Chyuan Su; Chieh-Yu Pan; Jyh-Yih Chen
Journal:  Cancers (Basel)       Date:  2019-02-01       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.